Nov 16, 2015
CardioCell CEO Presents at the World Congress of Regenerative Medicine & Stem Cell – Shanghai 2015
SHANGHAI, CHINA – WORLD CONGRESS OF REGENERATIVE MEDICINE & STEM CELL 2015 – Nov. 16, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by CEO Sergey Sikora, Ph.D., at the World Congress of Regenerative Medicine & Stem Cell (RMSC) 2015 in Shanghai, China, Nov. 18-20. The session, “Mesenchymal Stem Cells Exposed to Chronic Hypoxia Preferentially Home to Regions of Myocardial Injury Following Intravenous Injection,” on Nov. 19 from 8:35-9 a.m. discloses pre-clinical and clinical study data on CardioCell’s ischemia-tolerant mesenchymal stem cell (itMSC) therapy for acute myocardial infarction.
|What:||Pre-clinical and clinical study data from the paper “Mesenchymal Stem Cells Exposed to Chronic Hypoxia Preferentially Home to Regions of Myocardial Injury Following Intravenous Injection”|
|Who:||CardioCell’s CEO Sergey Sikora, Ph.D.|
|When:||Thursday, Nov. 19, 2015, from 8:35-9 a.m.|
|Where:||RMSC 2015 — Wyndham Bund East Shanghai
Hangzhou Room, 3F, WBES
About CardioCell LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.